The U.S. Food and Drug Administration has approved the commercialization of Boston Scientific Corporation’s TAXUS® Express2™ Atom™ Paclitaxel-Eluting Coronary Stent System. Designed for the treatment of small coronary vessels, the system is the first drug-eluting stent (DES) which has got the FDA approval for sale in the American market for use in vessels smaller than 2.25 mm in diameter.